UOC
NGNE icon

UBS O'Connor’s Neurogene NGNE Stock Holding History

UBS O'Connor’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,761
Closed -$520K – 396
2025
Q2 		$520K Sell
34,761
-21,254
-38% -$334K 0.01% 271
2025
Q1 		$656K Buy
56,015
+23,281
+71% +$404K 0.02% 211
2024
Q4 		$748K Buy
32,734
+23,907
+271% +$890K 0.02% 254
2024
Q3 		$370K Buy
8,827
+1,727
+24% +$67K 0.01% 362
2024
Q2 		$258K Buy
+7,100
New +$250K 0.01% 408

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS O'Connor's NGNE Position: Q3 2025 in Review

UBS O'Connor sold out of Neurogene (NGNE) in Q3 2025, closing a stake of 34,761 shares — an estimated $520K sold.

UBS O'Connor first reported a position in NGNE in Q2 2024 and held it in 5 quarters. The position peaked at $748K in Q4 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q3 2025.

  • UBS O'Connor reported no remaining Neurogene position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 34,761 Neurogene shares in Q3 2025, an estimated $520K.
  • UBS O'Connor first reported a position in Neurogene in Q2 2024 and held it in 5 quarters.
  • UBS O'Connor's Neurogene position peaked at $748K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.